Good morning :)
Place Order
Add to Watchlist

Cohance Lifesciences Ltd

COHANCE Share Price

1,080.500.49% (+5.30)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹41,336 cr, stock is ranked 207

Stock is 2.49x as volatile as Nifty

COHANCE Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹41,336 cr, stock is ranked 207

Stock is 2.49x as volatile as Nifty

COHANCE Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
148.0420.16
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.786.460.86%

COHANCE Analyst Ratings & Forecast

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 6 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

COHANCE Company Profile

Cohance Lifesciences Limited is a technology-driven CDMO in India, offering custom synthesis, process R&D, and manufacturing services for pharmaceuticals and specialty chemicals.

Investor Presentation

View older 

Feb 12, 2025

PDF
View Older Presentations

COHANCE Similar Stocks (Peers)

Compare with peers 
PE Ratio
37.73
1Y Return
11.65%
Buy Reco %
88.24
PE Ratio
22.49
1Y Return
0.93%
Buy Reco %
75.00
PE Ratio
56.89
1Y Return
20.58%
Buy Reco %
72.00
PE Ratio
17.98
1Y Return
4.06%
Buy Reco %
53.33
PE Ratio
50.56
1Y Return
15.76%
Buy Reco %
81.25
Compare with Peers
COHANCE Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

COHANCE Stock Summary · November 2024

The company is strategically positioning itself for growth by focusing on compliance, transparency, and the integration of new technologies, particularly in the promising GLP-1 product space. With a robust 40% year-on-year growth in the Pharma CDMO segment, management is optimistic about future revenue, bolstered by positive clinical trial developments and a healthy order book. However, challenges persist, as evidenced by a decline in revenue during the first half of FY25, prompting a cautious approach to interpreting quarterly results. The upcoming merger with Cohance is anticipated to enhance growth prospects, while ongoing investments in capacity and strategic restructuring aim to improve visibility and operational performance. Overall, the company is navigating a dynamic market landscape with a focus on sustainable growth and customer engagement.

Key Points on Cohance Stock
COHANCE Stock Growth Drivers
7
  • Strong Financial Performance

    The company reported a year-on-year revenue increase of 12% in Q2 FY25, reaching Rs 2.58

  • Expansion of Product Pipeline

    The company has significantly expanded its Phase-3 product pipeline, increasing the number of Phase-3 products

COHANCE Stock Challenges
4
  • Revenue Decline

    In the first half of FY25, the company experienced a significant revenue decline of 15.6%,

  • One-time Costs Impacting Margins

    The company reported lower EBITDA margins due to one-time costs totaling Rs 52 million related

COHANCE Forecasts

COHANCE Forecast

Price

Revenue

Earnings

COHANCE

Income

Balance Sheet

Cash Flow

COHANCE Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 24.09%, vs industry avg of 9.04%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.17% to 0.29%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 22.41%, vs industry avg of 15.28%

Loading...

Financial YearFY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue378.43900.121,077.691,453.711,386.691,113.261,113.53
Raw Materialssubtract124.52240.24310.32459.46430.08265.88673.51
Power & Fuel Costsubtract18.0638.2444.2059.5573.9348.30
Employee Costsubtract29.6365.1076.23100.48118.25135.92
Selling & Administrative Expensessubtract16.2344.7644.9653.1846.4541.00
Operating & Other expensessubtract17.8460.7091.0165.8497.46154.45
Depreciation/Amortizationsubtract11.5023.5131.6439.1047.9954.6067.96
Interest & Other Itemssubtract2.7923.0711.678.5312.817.458.90
Taxes & Other Itemssubtract48.5987.51105.34213.78148.44105.3983.94
EPS24.9114.2317.8316.1611.8010.97
DPS0.002.502.005.006.000.000.00
Payout ratio0.100.140.280.370.000.00

COHANCE Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Jun 8PDF
Feb 11PDF
FY 2022

Annual report

PDF

Investor Presentation

May 9PDF
May 9PDF
Feb 8PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

Aug 8PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 12PDF
Nov 12PDF
 

COHANCE Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Cohance Lifesciences Ltd137.6620.16
Sun Pharmaceutical Industries Ltd37.736.150.93%
Cipla Ltd22.494.431.09%
Torrent Pharmaceuticals Ltd56.8915.861.00%

COHANCE Stock Price Comparison

Compare COHANCE with any stock or ETF
Compare COHANCE with any stock or ETF
COHANCE
Loading...

COHANCE Shareholdings

COHANCE Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

COHANCE Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

COHANCE Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.10%13.04%3.56%11.05%22.25%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

COHANCE Shareholding History

Dec '23MarJunSepDec '24Mar10.14%9.54%9.80%10.70%10.84%11.05%

Mutual Funds Invested in COHANCE

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Cohance Lifesciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.0000%1.53%-0.28%21/53 (0)
0.0000%0.08%-0.02%62/536 (+28)
0.0000%0.00%-0.44%64/75 (-6)

Compare 3-month MF holding change on Screener

COHANCE Insider Trades & Bulk Stock Deals

Loading...

smallcases containing COHANCE stock

Looks like this stock is not in any smallcase yet.

COHANCE Events

COHANCE Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

COHANCE Upcoming Dividends

No upcoming dividends are available

COHANCE Past Dividends

Cash Dividend

Ex DateEx DateSep 9, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 9, 2022

Cash Dividend

Ex DateEx DateSep 9, 2022

Special
Special | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Sep 9, 2022

Cash Dividend

Ex DateEx DateMay 13, 2022

Special
Special | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

May 13, 2022

Cash Dividend

Ex DateEx DateMay 13, 2022

Interim 2
Interim 2 | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

May 13, 2022

Cash Dividend

Ex DateEx DateFeb 15, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Feb 15, 2022

COHANCE Stock News & Opinions

Corporate
Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value of Re 1 each to the eligible shareholders of Cohance Lifesciences (transferor company) in share exchange ratio of 11:295 in terms of the scheme of amalgamation. Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of India (MCA), has approved change of name of the Company from 'Suven Pharmaceuticals' to 'Cohance Lifesciences', with effect from 07 May 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench. In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of 1st May 2025, following the satisfaction of all prescribed conditions. The merged company will operate under the name Cohance Lifesciences, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under: Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications') Short Term Rating - CRISIL A1+ (Reaffirmed)Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Suven Pharma jumps after Q3 PAT climbs 77% YoY to Rs 83 cr

Revenue from operations jumped 39.7% to Rs 307.15 crore in Q3 FY25 as compared with Rs 219.82 crore in Q3 FY24. Profit before tax (PBT) stood at Rs 109.73 crore, up 67.6% as compared with Rs 65.47 crore in Q3 FY24. In Q3 FY25, revenue from Suven and Cohance (proforma basis) stood at 6.76 billion, up 40% YoY and Adjusted EBITDA growth of 85% YoY with margins of 38.7% In contract development and manufacturing organization (CDMO) segment, two molecules added this quarter: One molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules. In SpecChem CDMO segment, the company said that it witnessed recovery as expected, following the bottoming out in Q2. On outlook front, the company expects to deliver YoY growth for the combined platform in FY25 on a full year basis, with acceleration expected in FY26. It targets to reach $1 billion revenue, led by an expanding CDMO share, niche tech investments and continued strategic M&A. Vivek Sharma, executive chairman, commented, 'Suven Pharma has reaffirmed its growth trajectory in Q3 FY25 as we had expected. We continue to make BD efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision. Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth. As we gear to deliver our $1 billion revenue guidance with higher CDMO and niche technology share.' V. Prasada Raju, managing director, added: 'We continue to witness a strong momentum in our Pharma CDMO business, with increased RFQ inflows and a robust late-stage pipeline. As our Phase 3 pipeline has expanded now to 15 projects with 9 molecules, gives us comfort on our strategic endeavors moving in the right direction. Our ability to drive innovation with addition of Oligos, deepening our ADC presence, and serve as a trusted partner to global innovators continues to enhance our competitive edge.' Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of the global pharma industry.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Suven Pharmaceuticals Ltd Surges 5.19%

Suven Pharmaceuticals Ltd gained 5.19% today to trade at Rs 1099.95. The BSE Healthcare index is up 0.8% to quote at 41147.95. The index is down 4.33 % over last one month. Among the other constituents of the index, NGL Fine Chem Ltd increased 4.34% and Aurobindo Pharma Ltd added 4.1% on the day. The BSE Healthcare index went up 17.3 % over last one year compared to the 6.26% surge in benchmark SENSEX. Suven Pharmaceuticals Ltd has added 4.29% over last one month compared to 4.33% fall in BSE Healthcare index and 0.23% drop in the SENSEX. On the BSE, 2774 shares were traded in the counter so far compared with average daily volumes of 9706 shares in the past one month. The stock hit a record high of Rs 1359 on 02 Dec 2024. The stock hit a 52-week low of Rs 597 on 04 Jun 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Suven Pharmaceuticals consolidated net profit rises 77.28% in the December 2024 quarter

Net profit of Suven Pharmaceuticals rose 77.28% to Rs 82.88 crore in the quarter ended December 2024 as against Rs 46.75 crore during the previous quarter ended December 2023. Sales rose 39.73% to Rs 307.15 crore in the quarter ended December 2024 as against Rs 219.82 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales307.15219.82 40 OPM %38.3230.06 - PBDT130.0878.26 66 PBT109.7365.47 68 NP82.8846.75 77 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Suven Pharmaceuticals schedules board meeting

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Suven Pharmaceuticals acquires 56% stake in NJ Bio Inc.

Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc. (target company), at an aggregate consideration of USD 64.4 million, which includes USD 15 million of primary equity infusion into the target company. Powered by Capital Market - Live

4 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Cohance Lifesciences Ltd (COHANCE) today?

    The share price of COHANCE as on 22nd May 2025 is ₹1080.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Cohance Lifesciences Ltd (COHANCE) share?

    The past returns of Cohance Lifesciences Ltd (COHANCE) share are
    • Past 1 week: -0.20%
    • Past 1 month: -11.08%
    • Past 3 months: -11.90%
    • Past 6 months: -16.57%
    • Past 1 year: 74.12%
    • Past 3 years: 106.99%
    • Past 5 years: 571.95%

  3. What are the peers or stocks similar to Cohance Lifesciences Ltd (COHANCE)?
  4. What is the market cap of Cohance Lifesciences Ltd (COHANCE) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cohance Lifesciences Ltd (COHANCE) is ₹41336.38 Cr as of 22nd May 2025.

  5. What is the 52 week high and low of Cohance Lifesciences Ltd (COHANCE) share?

    The 52-week high of Cohance Lifesciences Ltd (COHANCE) is ₹1360 and the 52-week low is ₹598.

  6. What is the PE and PB ratio of Cohance Lifesciences Ltd (COHANCE) stock?

    The P/E (price-to-earnings) ratio of Cohance Lifesciences Ltd (COHANCE) is 137.66. The P/B (price-to-book) ratio is 20.16.

  7. Which sector does Cohance Lifesciences Ltd (COHANCE) belong to?

    Cohance Lifesciences Ltd (COHANCE) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Cohance Lifesciences Ltd (COHANCE) shares?

    You can directly buy Cohance Lifesciences Ltd (COHANCE) shares on Tickertape. Simply sign up, connect your demat account and place your order.